Term
|
Definition
Proscar
first approved 5a-reductase inhibitor
as Propecia and is prescribed for both men and women who suffer from hair loss |
|
|
Term
|
Definition
Avodart
amide analog of Finasteride, and the FDA approved it for BPH |
|
|
Term
|
Definition
Lupron
first LH-RH agonist approved for prostate cancer
peptide, it is only provided as an inject
doses that require injection every 3-6 months. Common side effects include water retention and urinary inconsistencies |
|
|
Term
|
Definition
Zoladex
initially pursued as an LH-RH agonist for breast cancer, but was approved for prostate cancer
peptide
injectable, formulated for injection every 28 days or every 3 months
typically causes a “flare up” of initially-increased testosterone production before becoming effective, but it has fewer other side effects than Lupron. |
|
|
Term
|
Definition
Vantas
approved for prostate cancer
annual subcutaneous implant. Side effects include hot flashes, and urinary inconsistencies |
|
|
Term
|
Definition
Trelstar
newest LH-RH agonist
powder that must be dissolved prior to injection, which can be conducted every 1-6 months
“flare up” when first injected, but so far appears to have reduced side effects. |
|
|
Term
|
Definition
Casodex
first androgen receptor agonist that was approved for prostate cancer
is small molecule
only available as a racemic mixture
urinary irregularity and decreased libido |
|
|
Term
|
Definition
Casodex
more significant side effects including gynecomastia as well as increased soreness and liver toxicity |
|
|
Term
|
Definition
Nilandron
microcrystalline powder that is taken in pill form
does not show significant CYP inhibition |
|
|
Term
|
Definition
Provenge
vaccine created by collecting a patient’s leukocytes and incubating them with an antigen for a specific enzyme |
|
|
Term
|
Definition
Xtandi
first drug approved for the treatment of mCRPC
potent inhibitor of CYP2C8
Like most other anti-androgens, urinary inconsistencies and decreased libido are common side effects. |
|
|
Term
|
Definition
Cometriq
inhibitor of an enzyme known as c-MET that was approved for medullary thyroid cancer
currently in Phase III clinical trials for mCRPC |
|
|
